Nexus Pharmaceuticals Launches Cyclophosphamide Injection, 2.5 mL and 5 mL

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, LLC announces the launch of Cyclophosphamide Injection, available in ready to dilute 2.5 mL fill and 5 mL fill multiple-dose vials. As the first AP Rated Generic to Dr. Reddy's, this product provides healthcare providers with a critical chemotherapy medication that slows the growth of cancer cells.

“Transforming difficult-to-formulate molecules into the highest-quality medicines is what we do best,” says Stephen Kim, Chief Executive Officer at Nexus. “Bringing Cyclophosphamide to market is another example of our commitment to expand access to the critical treatments patients and providers rely on every day.”

Cyclophosphamide Injection is now available. Order through your Wholesaler or call (888) 806-4606.

Cyclophosphamide Injection 500 mg/2.5 mL - Unit of Sale NDC 14789-0125-05

Cyclophosphamide Injection 1 gram/5 mL - Unit of Sale NDC 14789-0126-05

About Nexus Pharmaceuticals, LLC:

Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260406785300/en/

Media Contact:
[email protected]
(847) 996-3790

Source: Nexus Pharmaceuticals, LLC

You May Also Be Interested In

• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
• Litecoin Price Prediction: Can LTC Reclaim $63 as Remittix Plans a 64.3% Presale Price Increase?
• Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026